Meridian Bioscience Inc. (VIVO) insider have most recently took part in a trading activity. On Aug 24, 2017 Kraeutler John A, Chairman and CEO bought 7,000 shares having total worth of $95,690 at the price of $13.67 per share, following the transaction a total of 345,991 shares owned by Kraeutler John A. Before this latest buy, Kraeutler John A purchased VIVO at 1 other times during the past twelve months, for a total investment of $80,650 at an average of $16.13 per share.
Furthermore, over the past 12 months , the stock was traded 7 times by insiders. In 2 of these trades, the insider was a seller while an employee of the company was the buyer in 5 instances.
Shares of Meridian Bioscience Inc. (VIVO) traded up 0.74% on Aug 24, 2017, hitting $13.7. 197,007 shares of the company’s stock traded hands. Meridian Bioscience Inc. has a 52 week low of $11.99 and a 52 week high of $20.11. The company’s market cap is $828 million.
Meridian Bioscience Inc. (VIVO) last announced its earnings results on Jul 27, 2017. The company reported 0.16 earnings per share (EPS) for the quarter, lower than the consensus estimate of 0.17 by $0.01. The company had revenue of $50 million for the quarter, compared to the consensus estimate of $49 million. During the same quarter in the previous year, the company posted 0.21 earnings per share. The company’s revenue for the quarter was down 1% on a year-over-year basis.
|earnings per share||0.16||0.22||0.15||0.14||0.24||0.21||0.20||0.22||0.24||0.20|
Meridian Bioscience Inc. was incorporated in Ohio in 1976. It is a fully-integrated life science Company whose businesses in the development, manufacture, sale and distribution of diagnostic test kits, mainly for certain respiratory, gastrointestinal, viral and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company’s operating segments are US Diagnostics, European Diagnostics, and Life Science. The Company’s U.S. Diagnostics operating segment’s business focuses on the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Its European Diagnostics operating segment’s business focuses on the sale and distribution of diagnostic test kits, manufactured both by the Company’s U.S. Diagnostics operating segment and by third-party vendors. Life Science operating segment’s business focuses on the development, manufacture, sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic companies, as well as contract development and manufacturing services under clinical cGMP conditions. The company’s competitors are Abbott Laboratories Inc., Becton, Dickinson and Company, Thermo Fisher and Siemens, Quidel Corporation and Inverness Medical Innovations.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018